FDA Approves Biogen’s Drug for Rare Form of ALSnews2023-04-25T17:53:59+00:00April 25th, 2023|The New York Times|
A Dilemma for Governments: How to Pay for Million-Dollar Therapiesnews2023-01-25T00:27:17+00:00January 25th, 2023|The New York Times|
They Created a Drug for Susannah. What About Millions of Other Patients?news2022-12-19T22:40:09+00:00December 19th, 2022|The New York Times|
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trialnews2022-12-02T21:55:07+00:00December 2nd, 2022|The New York Times|
The Disease Took Zara, Then Sara. Could Ayla Be Saved?news2022-11-09T22:00:17+00:00November 9th, 2022|The New York Times|
Gene Treatment for Rare Epilepsy Causes Brain Side Effect in 2 Childrennews2022-10-26T18:19:16+00:00October 26th, 2022|The New York Times|
Hospital and Drugmaker Move to Build Vast Database of New Yorkers’ DNAnews2022-08-12T09:00:15+00:00August 12th, 2022|The New York Times|
The Quest by Circadian Medicine to Make the Most of Our Body Clocksnews2022-07-06T09:00:24+00:00July 6th, 2022|The New York Times|
Targeting the Uneven Burden of Kidney Disease on Black Americansnews2022-05-17T07:01:35+00:00May 17th, 2022|The New York Times|
Family in Nigeria Lost 3 Daughters to Sickle Cell. Can They Save a Fourth?news2021-12-21T12:27:49+00:00December 21st, 2021|The New York Times|
